Drugs / MB12
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06687369 | Dec 2024 → Jun 2026 overdue | non-small cell lung carcinoma | mAbxience Research S.L. | Recruiting | No outcome recorded |
| Phase 3 | NCT05668650 | Aug 2023 → Aug 2024 overdue | non-small cell lung carcinoma | Laboratorio Elea Phoenix S.A. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MB12 | “MB12 is being developed by mAbxience Research S.L., and its clinical development is sponsored by Laboratorio Elea Phoenix S.A. as a proposed biosimilar to Keytruda®.” NCT05668650 ↗ |
| Modality | Small molecule | — CHEMBL204224 ↗ |
| Route | Intravenous | “Study drug administration: intravenous infusion” NCT05668650 ↗ |